Evaluation of the vancomycin dosage regimen based on serum creatinine used in the neonatal intensive care unit

Pediatrics International

Volumn 53, Issue 6, 2011, Pages 1038-1044

  Irikura, Mitsuru ^a   Fujiyama, Ayako ^a   Saita, Fumi ^a   Fukushima, Shiori ^a   Kitaoka, Hiroki ^b   Fukuda, Terumi ^b   Kawase, Akihiko ^c   Kondo, Yuichi ^c   Ishitsuka, Yoichi ^a   Kondo, Genzo ^b   Maeda, Toshihide ^b   Yukawa, Eiji ^d   Irie, Tetsumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Department of Pharmacy ^*  (Japan)

^c KUMAMOTO CITY HOSPITAL   (Japan)

^d DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

blood concentration; dosage regimen; neonate; serum creatinine; vancomycin

Indexed keywords

VANCOMYCIN;

ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; INFANT; JAPAN; LIVER DYSFUNCTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEWBORN INTENSIVE CARE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84255189975     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03441.x     Document Type: Article

References (30)

1. Takahashi H, Sai N, Yata Y, Honma Y, Momoi M, Nishida H,. Nationwide survey concerning MRSA carrier in neonatal intensive care unit in Japan. J. Jpn. Pediatr. Soc. 2005; 109: 1009-14.
2. Gregory M, Eichenwald E, Puopolo K,. Seven-year experience with a surveillance program to reduce methicillin-resistant Staphylococcus aureus colonization in a neonatal intensive care unit. Pediatrics 2009; 123: e790-796.
3. Kitajima H,. Prevention of methicillin-resistant Staphylococcus aureus infections in neonates. Pediatr. Int. 2003; 45: 238-45. (Pubitemid 36578955)
4. Rybak MJ,. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 2006; 42: S35-9. (Pubitemid 41832063)
5. De Hoog M, Mouton JW, Van Den Anker JN,. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 2004; 43: 417-40. (Pubitemid 38716502)
6. Leonard MB, Koren G, Stevenson DK, Prober CG,. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr. Infect. Dis. J. 1989; 8: 282-6. (Pubitemid 19127029)
7. McDougal A, Ling EW, Levine M,. Vancomycin pharmacokinetics and dosing in premature neonates. Ther. Drug Monit. 1995; 17: 319-26.
8. Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD,. Vancomycin pharmacokinetics in infants: Relationship to postconceptional age and serum creatinine. Dev. Pharmacol. Ther. 1990; 14: 77-83. (Pubitemid 20069565)
9. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC,. Constant rate infusion of vancomycin in premature neonates: A new dosage schedule. Br. J. Clin. Pharmacol. 1998; 46: 163-7. (Pubitemid 28342788)
10. De Hoog M, Schoemaker RC, Mouton JW, Van Den Anker JN,. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 2000; 67: 360-7. (Pubitemid 30246811)
11. Capparelli EV, Lane JR, Romanowski GL, et al,. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J. Clin. Pharmacol. 2001; 41: 927-34. (Pubitemid 32786565)
12. Grimsley C, Thomson AH,. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1999; 81: F221-7. (Pubitemid 29503334)
13. Gabriel MH, Kildoo CW III, Gennrich JL, Modanlou HD, Collins SR,. Prospective evaluation of a vancomycin dosage guideline for neonates. Clin. Pharm. 1991; 10: 129-32.
14. Lo Y, van Hasselt J, Heng S, Lim C, Lee T, Charles B,. Population pharmacokinetics of vancomycin in premature Malaysian neonates: Identification of predictors for dosing determination. Antimicrob. Agents Chemother. 2010; 54: 2626-32.
15. Stoll BJ,. Infections of the neonatal infant. In:, Behrman RE, Kliegman R, Jenson HB, (eds). Nelson Textbook of Pediatrics, 17 edn. Saunders, Philadelphia, 2004; 623-40.
16. Ishizeki S, Masunaga K, Shimada M, Takigawa I, Akiyama K, Imura S,. Pharmacokinetic studies of vancomycin hydrochloride (VCM) in premature infants. J. Jpn. Pediatr. Soc. 1996; 100: 633-7.
17. Higuchi S, Aoyama T, Horioka M,. PEDA: A microcomputer program for parameter estimation and dosage adjustment in clinical practice. J. Pharmacobiodyn. 1987; 10: 703-18. (Pubitemid 18034459)
18. Shackley F, Roberts P, Heath P, Bowler I, Saunders NJ,. Trough-only monitoring of serum vancomycin concentrations in neonates. J. Antimicrob. Chemother. 1998; 41: 141-2. (Pubitemid 28064266)
19. Tan WH, Brown N, Kelsall AW, McClure RJ,. Dose regimen for vancomycin not needing serum peak levels? Arch. Dis. Child. Fetal Neonatal Ed. 2002; 87: F445-6.
20. Silva R, Reis E, Bispo MA, et al,. The kinetic profile of vancomycin in neonates. J. Pharm. Pharmacol. 1998; 50: 1255-60. (Pubitemid 28546602)
21. Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC,. Vancomycin pharmacokinetics in neonates and infants: A retrospective evaluation. Ann. Pharmacother. 1993; 27: 490-6. (Pubitemid 23123902)
22. Lisby-Sutch SM, Nahata MC,. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur. J. Clin. Pharmacol. 1988; 35: 637-42. (Pubitemid 19000282)
23. De Hoog M, Van Zanten BA, Hop WC, Overbosh E, Weisglas-Kuperus N, Van Den Anker JN,. Newborn hearing screening: Tobramycin and vancomycin are not risk factors for hearing loss. J. Pediatr. 2003; 142: 41-6. (Pubitemid 36106386)
24. Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T,. Lack of vancomycin-associated nephrotoxicity in newborn infants: A case-control study. Pediatrics 1999; 103: e48.
25. Matzke GR, Zhanel GG, Guay DRP,. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 1986; 11: 257-82. (Pubitemid 16050520)
26. Läer S, Barrett J, Meibohm B,. The in silico child: Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J. Clin. Pharmacol. 2009; 49: 889-904.
27. Seikaly M, Arant BJ,. Development of renal hemodynamics: Glomerular filtration and renal blood flow. Clin. Perinatol. 1992; 19: 1-13.
28. Gallini F, Maggio L, Romagnoli C, Marrocco G, Tortorolo G,. Progression of renal function in preterm neonates with gestational age ≤ 32 weeks. Pediatr. Nephrol. 2000; 15: 119-24.
29. Guignard JP, Drukker A,. Why do newborn infants have a high plasma creatinine? Pediatrics 1999; 103: e49.
30. Van den Anker JN, De Groot R, Broerse HM, et al,. Assessment of glomerular filtration rate in preterm infants by serum creatinine: Comparison with inulin clearance. Pediatrics 1995; 96: 1156-8.